

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: **A. Mackerell et al.**) Confirmation No: **1522**
)
Application No. **10/582,640**) Group Art Unit: **1614**
)
Filed: **April 20, 2007**) Examiner: **G. Polansky**
)
For: **Immunomodulatory compounds that target**)
and inhibit the pY+3 binding site of tyrosene)
kinase p56 lck sh2 domain)

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated July 28, 2010, Applicants submit the following remarks for entry into the record of the above-captioned application. Applicants also hereby petition for a two month extension of time by payment of the accompanying fee.

Applicants elect without traverse the claims of Group I, *i.e.*, claims 1, 2, 4-13, 15-16, 18-19 and 21-22.

Applicants further elect the following variables of Formula I:

B is a phenyl ring;

D is a phenyl ring;

A associated with Z₃ is a 5-membered unsaturated heterocyclic ring containing one O;

A associated with Z₁ is a 5-membered heterocyclic ring containing one S and one N;

Q is an alkenylene group with 3 carbon atoms, substituted with =O, and a carbon atom is replaced with an N;

(Z₁)_n; n is 2; Z₁ is =O;

(Z₂)_n associated with B:

n is 2;